PE20010761A1 - Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico - Google Patents

Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico

Info

Publication number
PE20010761A1
PE20010761A1 PE2000001148A PE0011482000A PE20010761A1 PE 20010761 A1 PE20010761 A1 PE 20010761A1 PE 2000001148 A PE2000001148 A PE 2000001148A PE 0011482000 A PE0011482000 A PE 0011482000A PE 20010761 A1 PE20010761 A1 PE 20010761A1
Authority
PE
Peru
Prior art keywords
crystals
oxazolylmetoxy
benzyloximine
phenyl
methyl
Prior art date
Application number
PE2000001148A
Other languages
English (en)
Inventor
Yu Momose
Hiroshi Imoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20010761A1 publication Critical patent/PE20010761A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A CRISTALES DE ACIDO (E)-4-[4-(5-METIL-2-FENIL-4-OXAZOLILMETOXI)BENZILOXIIMINO]-4-FENILBUTIRICO, CON LA CONDICION QUE LOS CRISTALES CON PUNTO DE FUSION DE 126°C A 127°C QUEDEN EXCLUIDOS; CARACTERIZADOS POR TENER UN PUNTO DE FUSION ENTRE 136°C Y 139°C; UN PATRON DE DIFRACCION DE RAYOS X. EL COMPUESTO REGULA LA FUNCION DEL RECEPTOR RELACIONADO CON LOS RETINOIDES; RECEPTORES ACTIVADOS CON EL PROLIFERADOR DE LOS PEROXISOMAS Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES MELLITUS, HIPERLIPEMIA, DISMINUCION EN LA TOLERANCIA DE LA GLUCOSA, ENFERMEDADES INFLAMATORIAS, ARTERIOESCLEROSIS, AUMENTA LA SENSIBILIDAD A LA INSULINA
PE2000001148A 1999-10-29 2000-10-26 Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico PE20010761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30834699 1999-10-29

Publications (1)

Publication Number Publication Date
PE20010761A1 true PE20010761A1 (es) 2001-08-01

Family

ID=17979966

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001148A PE20010761A1 (es) 1999-10-29 2000-10-26 Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico

Country Status (19)

Country Link
US (1) US6777435B1 (es)
EP (1) EP1224178B1 (es)
KR (1) KR100433885B1 (es)
CN (1) CN1407975A (es)
AR (1) AR031078A1 (es)
AT (1) ATE243684T1 (es)
AU (1) AU7958100A (es)
CA (1) CA2388200A1 (es)
CL (1) CL2000002938A1 (es)
CO (1) CO5261530A1 (es)
DE (1) DE60003577T2 (es)
HK (1) HK1044536A1 (es)
HU (1) HUP0203884A3 (es)
MY (1) MY135840A (es)
NO (1) NO20022007L (es)
PE (1) PE20010761A1 (es)
PL (1) PL364171A1 (es)
TW (1) TW558554B (es)
WO (1) WO2001032637A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403903A1 (en) * 2000-03-28 2002-09-26 Masatoshi Hazama Angiogenesis inhibitors
JP4590159B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
ATE442148T1 (de) * 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
AU2003242396A1 (en) 2002-05-24 2003-12-12 Takeda Pharmaceutical Company Limited Insulin resistance improving agents
AU2005289808B2 (en) * 2004-09-24 2011-11-03 The Government Of The United States As Represented By The Secretary Of The Army, U.S. Army Medical Research Institute Of Chemical Defense Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2007028394A2 (en) * 2005-09-08 2007-03-15 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
EP3094380B1 (en) * 2014-01-17 2021-04-28 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
KR102281228B1 (ko) 2019-09-03 2021-07-22 신창수 과수나무의 가지지지용 파이프클램프

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69919156T2 (de) * 1998-05-11 2005-11-03 Takeda Pharmaceutical Co. Ltd. Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung
CN1407969A (zh) * 1999-10-29 2003-04-02 武田药品工业株式会社 氧亚氨基链烷酸衍生物的制备方法

Also Published As

Publication number Publication date
ATE243684T1 (de) 2003-07-15
CA2388200A1 (en) 2001-05-21
MY135840A (en) 2008-07-31
DE60003577D1 (de) 2003-07-31
TW558554B (en) 2003-10-21
US6777435B1 (en) 2004-08-17
CO5261530A1 (es) 2003-03-31
HK1044536A1 (en) 2002-10-25
EP1224178A1 (en) 2002-07-24
CN1407975A (zh) 2003-04-02
AR031078A1 (es) 2003-09-10
DE60003577T2 (de) 2004-04-29
HUP0203884A2 (hu) 2003-03-28
CL2000002938A1 (es) 2009-05-15
EP1224178B1 (en) 2003-06-25
NO20022007D0 (no) 2002-04-26
AU7958100A (en) 2001-05-14
HUP0203884A3 (en) 2005-01-28
KR100433885B1 (ko) 2004-06-04
PL364171A1 (en) 2004-12-13
KR20010102429A (ko) 2001-11-15
NO20022007L (no) 2002-06-24
WO2001032637A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
PE20010761A1 (es) Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico
CR11263A (es) COMPUESTOS NOVEDOSOS QUE POSEEN ACTIVIDAD INNHIBITORIA CONTRA TRANSPORTADOR DE GLUCOSA DEPENDIENTE DE SODIO (Solicitud divisional)
BR0313825A (pt) Composto, composição farmacêutica, método para tratar de diabete mellitus tipo 2 em um mamìfero, e, uso de composto
EP1405636A4 (en) REGULATOR OF RECTINTOR FUNCTION RELATING TO RETINOIDS
BR0213253A (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia
NO20016001D0 (no) Substituert fenylpropansyrederivater som agonister for human peroksisom proliferantaktivert reseptor (PPAR)<alfa>
Valcavi et al. Gastric antisecretory, antiulcer and cytoprotective properties of 9-hydroxy-19, 20-bis-nor-prostanoic acid in experimental animals.
DE60129712D1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
BR0010651A (pt) Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
ECSP055594A (es) Nuevos derivados de 2-piridiletilbenzamida
NO20063431L (no) 3-(4-Benzyloksyfenyl)propionsyrederivater
HU9601282D0 (en) Phenyl-alkyl imidazoles as h3-receptor antagonists
ES2176310T4 (es) Dispositivo para la liberacion intradermica de farmaco.
FI935842A0 (fi) Anvaendning av tetrahydrokarbazonderivat som 5HT1 -reseptoragonister
NO881933D0 (no) Orale administreringsformer med forsinket avgivning.
AU2065983A (en) Novel phenyl-substituted sulfonamides
DK1541303T3 (da) Fremgangsmåde til skæring af et flerlagslegeme
NO964121D0 (no) Pyrimidin- eller triazin-karboksylsyrederivater for anvendelse som legemidler
AR036054A1 (es) Uso de compuestos de aminoacetonitrilo para el control de plagas, una composicion y un proceso para dicho control y una composicion farmaceutica contra parasitos
CA2494625A1 (en) Downhole external line cutting apparatus and method
ATE342321T1 (de) Photochrome flüssigkristallverbindungen
DE50311252D1 (de) Benzylhemiformal enthaltende mikrobizide mittel
NO20024231L (no) Lipidb¶rer
ES2149630T3 (es) Solucion solida de hidroxido metalico, solucion solida de oxido metalico y procedimientos para su preparacion.
WO1992004014A3 (en) Regulation of neoplastic cell proliferation via a novel 5ht1a receptor

Legal Events

Date Code Title Description
FD Application declared void or lapsed